Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Intravenous gamma globulin in newborns].

P E Vargas1

  • 1Unidad de Recién Nacidos y Cuidado Intensivo Neonatal, Hospital Militar Gorgas, Ancón, Panamá.

Revista Medica De Panama
|September 1, 1990
PubMed
Summary

Intravenous immunoglobulin (IVIG) infusion is safe for stable newborns with bacterial infections. Monitoring showed no significant cardiopulmonary changes, with mild tachypnea in most infants during IVIG treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rectum leiomyoma in a 10-month-old female.

Pediatric surgery international·2003
Same author

[Percutaneous endoscopic gastrotomy (GEP): designed reusable (NAGEP) for one time endoscopic technique. Experimental study in dogs].

Acta gastroenterologica Latinoamericana·2000
Same author

[Prevalence of deficiency of thyroxine-binding globulin (TBG)].

Revista medica de Panama·1992
Same author

[Bacteremia and neonatal sepsis].

Revista medica de Panama·1990

Area of Science:

  • Neonatal Medicine
  • Immunology

Context:

  • Bacterial infections pose significant risks to newborns.
  • Intravenous immunoglobulin (IVIG) is used to manage various conditions in neonates.
  • Assessing the safety and tolerance of IVIG in vulnerable infant populations is crucial.

Purpose:

  • To evaluate the cardiopulmonary safety and tolerance of intravenous gammaglobulin (Sandoglobulina) infusion in newborns with bacterial infections.

Summary:

  • Eight newborns received 3% IVIG at infusion rates of 0.5-1.5 mg/kg/min and 7-9 mg/kg/min.
  • Cardiopulmonary parameters (heart rate, blood pressure, respiratory rate) were monitored.
  • No significant changes in heart rate or blood pressure were observed.
  • Mild tachypnea occurred in 7 of 8 infants, but all values remained within physiological ranges.
  • Stable newborns with bacterial infections tolerated IVIG well at doses of 0.25 mg/kg/day to 1.0 gm/kg/day for 4-6 days.

Impact:

  • This study supports the safety of using IVIG in neonates with bacterial infections.
  • Provides evidence for tolerable infusion rates and dosages in this population.
  • Informs clinical practice regarding IVIG administration in neonatal care.

Related Experiment Videos